Drug Trial Radar · NCT07036523
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
81
Actual
Start
Nov 13, 2025
Primary completion
Mar 11, 2027
Study completion Jun 22, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jun 25, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults who are at least 40 years old and have idiopathic pulmonary fibrosis (IPF). People can participate in the study if they have a forced vital capacity (FVC) greater than or equal to 45% of the predicted value and fibrosis of 20% or more confirmed by a high-resolution computed tomography (HRCT) scan. The purpose of this study is to find out if a medicine called BI 765423 can improve lung function in people with IPF. The study will compare BI 765423 with a placebo to see if there is a difference in lung capacity after 3-6 months of treatment and will also look at changes in certain markers related to lung health. Participants are put into two groups randomly, which means by chance. One group receives the study medicine, and the other group receives a placebo. Placebo looks like BI 765423 but does not contain any study medicine. The study medicine is given as an infusion into a vein every four weeks. Participants are in the study for up to 11 months. During the study, participants may continue their regular treatment for IPF. During the study they visit the study site several times for screening, treatment, and follow-up. Doctors regularly test lung function by measuring FVC and take blood samples to measure study endpoints. The results are compared between the two groups to see whether the treatment works. The doctors also check participants' health and take note of any unwanted effects.
Conditions
- Idiopathic Pulmonary Fibrosis
Interventions
BI 765423Drug
BI 765423
PlaceboDrug
Placebo to BI 765423
Primary outcomes
What the sponsor says the trial is designed to measure.
- Absolute change from baseline in FVC (mL) at 12 weeksTime frame: Baseline, 12 weeks
Locations
46 sites in 10 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Florida
Gainesville, Florida
Renstar Medical Research
Ocala, Florida
University of Iowa Hospitals and Clinics
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
University of Minnesota
Minneapolis, Minnesota
The Lung Research Center, LLC
Chesterfield, Missouri
University of Missouri Health System
Columbia, Missouri
New York Presbyterian Hospital -Columbia University
New York, New York
Weill Cornell Medical College
New York, New York
Duke University Medical Center
Durham, North Carolina
University of Cincinnati Medical Center
Cincinnati, Ohio
Temple University
Philadelphia, Pennsylvania
Clinical Trials Center of Middle Tennessee, LLC
Franklin, Tennessee
University of Virginia Health System
Charlottesville, Virginia
The Prince Charles Hospital
Chermside, Queensland, Australia
Monash Health
Clayton, Victoria, Australia
Institute for Respiratory Health
Nedlands, Western Australia, Australia
Cliniques Universitaires Saint-Luc
Brussels, Belgium
Yvoir - UNIV UCL de Mont-Godinne
Yvoir, Belgium
Synergy Respiratory Care
Sherwood Park, Alberta, Canada
Kelowna Respirology & Allergy Research
Kelowna, British Columbia, Canada
QEII Health Sciences Centre
Halifax, Nova Scotia, Canada
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada
Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH
Essen, Germany
Medizinische Hochschule Hannover
Hanover, Germany
ASST Papa Giovanni XXIII
Bergamo, Italy
A. O. Universitaria Careggi
Florence, Italy
Azienda Ospedaliera dei Colli
Naples, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Roma, Italy
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
Torino, Italy
Tosei General Hospital
Aichi, Seto, Japan
University of Fukui Hospital
Fukui, Yoshida-gun, Japan
National Hospital Organization Kyushu Medical Center
Fukuoka, Fukuoka, Japan
Kanagawa Cardiovascular and Respiratory Center
Kanagawa, Yokohama, Japan
National Hospital Organization Kinki-Chuo Chest Medical Center
Osaka, Sakai, Japan
Hamamatsu University Hospital
Shizuoka, Hamamatsu, Japan
Soon Chun Hyang University Hospital Bucheon
Bucheon-si, Gyeonggi-do, South Korea
Inje University Haeundae Paik Hospital
Busan, South Korea
Soonchunhyang University Hospital Seoul
Seoul, South Korea
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.